 TEL AVIV, Israel , Aug. 1, 2022 PRNewswire -- Chemomab Therapeutics Ltd. Nasdaq: CMMB, Chemomab, a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced the company will release its second quarter 2022 financial results and provide a business update on Friday, August 12, 2022 at 8:00 am Eastern Time. 